OSI Pharma (OSI) and Roch Announce Tarceva Net Sales; ATLAS Data Sweep
More News related to OSIP
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
- OSI Pharma (OSIP) volume and volatility increases into Tarceva committee review
- ODAC to Review Using OSI Pharma's (OSIP) Tarceva as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
More News related to Corporate News
- Natixis Bleichroeder Initiates Coverage on AGA Medical (AGAM) with a Buy
- Leerink Swann Resumes Coverage on Medivation (MDVN) with an Outperform
- J.P. Morgan Initiates Coverage on Liberty Global (LBTYA) with a Neutral
- Wells Fargo Initiates Coverage on AGA Medical Holdings (AGAM) with a Market Perform
- FBR Research Initiates Coverage on HSBC Holdings (HBC) with an Outperform
Roche and OSI Pharmaceuticals (NASDAQ: OSIP) announced the net sales result for its oncology drug Tarceva. Sales for Q308 were approximately $301 million. Sales were $118 million in the U.S. and $183 abroad.
In addition, Roche has communicated to OSI that an exploratory ATLAS data sweep for survival was not positive. Survival was a secondary endpoint in the ATLAS study and the study was not powered to detect a significant difference in overall survival.
As OSI has previously communicated, OSI did not "opt-in" to the ATLAS study because the study was not designed to be registrational. If the study were to result in an ATLAS related change to the Tarceva label OSI would likely be required to opt-in and pay its retrospective share of the study costs and a penalty. OSI is not currently forecasting any opt-in payments for this study.
Related Categories
Corporate NewsRetail Sales
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
